Drug Profile
Rusalatide - Chrysalis BioTherapeutics
Alternative Names: Chrysalin; Rusalatide acetate; Thrombin receptor activating peptide; TP 508; TRAP-508Latest Information Update: 28 Sep 2023
Price :
$50
*
At a glance
- Originator University of Texas Medical Branch
- Developer Baylor College of Medicine; Capstone Therapeutics; Chrysalis BioTherapeutics; Quintiles; University of Texas Medical Branch
- Class Amino acids; Peptides; Vascular disorder therapies
- Mechanism of Action Angiogenesis inducing agents; Apoptosis inhibitors; Cytokine modulators; Intercellular signalling peptide and protein stimulants; Nitric oxide stimulants; Osteogenesis stimulants; Signal transduction pathway modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Acute radiation syndrome
- Discontinued Chronic wounds; Diabetic foot ulcer; Fracture; Joint disorders; Myocardial infarction; Periodontal disorders; Spinal disorders; Vascular disorders
Most Recent Events
- 26 Sep 2023 US FDA approves IND application for Rusalatide in Acute respiratory distress syndrome
- 26 Sep 2023 Chrysalis BioTherapeutics plans a phase I trial for Acute respiratory distress syndrome in December 2024
- 28 Jan 2022 No recent reports of development identified for preclinical development in Acute-radiation-syndrome in USA (Parenteral, Injection)